Evidence map›Paper›PMID 25978323›Full record

ArticlePloS one2015

Repeated-measures implication of hepatocellular carcinoma biomarkers in living donor liver transplantation.

King-Wah Chiu, Toshiaki Nakano, Kuang-Den Chen, Li-Wen Hsu, Chia-Yun Lai, Ching-Yin Huang, Yu-Fan Cheng, Shigeru Goto, Chao-Long Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

King-Wah ChiuLiver Transplantation Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University, College of Medicine, Taoyuan, Taiwan.
Toshiaki NakanoLiver Transplantation Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University, College of Medicine, Taoyuan, Taiwan.
Kuang-Den ChenLiver Transplantation Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Li-Wen HsuLiver Transplantation Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Chia-Yun LaiLiver Transplantation Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Ching-Yin HuangLiver Transplantation Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Yu-Fan ChengLiver Transplantation Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University, College of Medicine, Taoyuan, Taiwan.
Shigeru GotoLiver Transplantation Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Chao-Long ChenLiver Transplantation Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University, College of Medicine, Taoyuan, Taiwan.
Kaohsiung Chang Gung Memorial Hospital · TWChang Gung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHepatocellular carcinoma (HCC) and its recurrence are major problems in living donor liver transplantation (LDLT). Several biomarkers have been used to investigate this event. We conducted a prospective controlled study to determine the activities of the basic fibroblast growth factor (FGF-2), survivin, Ki67, endostatin, and vascular endothelial growth factor (VEGF) in different conditions before, early after, and late after LDLT with and without HCC recurrence.

methodsFifty patients with virus-related HCC who underwent LDLT were enrolled in this 2-year cross-sectional study. During the study period, recurrent HCC was identified in 9 patients (study group, n = 9) and 41 patients (control group, n = 41) had no recurrence after LDLT. The mean time to HCC recurrence was 587.11 ± 398.64 days (range, 90-1352 days). Microvascular invasion (MVI) was found in 66.7% (6/9) of the recipients, as determined on pathological examination. The serum biomarkers were investigated by using enzyme-linked immunosorbent assay at the different LDLT stages.

resultsThe serum levels of the biomarkers significantly correlated with LDLT and HCC recurrence in the repeated-measures analysis (F = 31.676, P = 0.000). Significant differences were observed in the effects of all biomarkers (F = 85.313, P = 0.000) and the time to HCC recurrence after LDLT (F = 3.178, P = 0.046). The biomarkers, ordered by the observed power of the test for HCC recurrence after LDLT, were FGF-2 (1.000) > survivin (0.999) > Ki67 (0.949) > endostatin (0.411) > VEGF (0.305).

conclusionsDifferent biomarker activities may be implicated in the pathogenesis of HCC recurrence after LDLT. Oncogenes may not exist in the new graft but may still be present in the peripheral blood. The timing of HCC recurrence and impact of MVI in the explanted liver requires confirmation in larger studies with a longer follow-up.

Indexed as

Liver TransplantationBiomarkersCarcinoma, HepatocellularEndostatinsFemaleFibroblast Growth Factor 2HumansInhibitor of Apoptosis ProteinsKi-67 AntigenLiver NeoplasmsLiving DonorsMaleMiddle AgedProspective StudiesSurvivinTreatment OutcomeBiomarkersBIRC5 protein, humanEndostatinsFibroblast Growth Factor 2Inhibitor of Apoptosis ProteinsKi-67 AntigenSurvivinVascular Endothelial Growth Factor A

Identifiers

PMID25978323
PMCPMC4433208
OpenAlexW223184145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.